NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Stopped early · Phase 1

Conditions studied: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma

In brief

This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Key facts

Study ID

NCT02429804

Run by

Stanford University

People needed

4

Starts

2015-04-01

Expected to finish

2017-05-15

Last updated by the study team

2017-05-30

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Provides written informed consent
• Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223 dichloride)
• Able to remain still for duration of the imaging procedure (about one hour)

You may not qualify if…

• Metallic implants

Where it is running

• Stanford University, School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.